The company is transitioning from a legacy stock and insurance brokerage business into the marketing and distribution of pharmaceutical, nutraceutical, and wellness products through its subsidiary, Truhealthy Wellness.
The company lacks a durable competitive advantage, as evidenced by its inability to generate revenue from its new business segment for over a year and its reliance on investment income to mask operational losses. Financial metrics show deeply negative net margins and zero return on capital, indicating no pricing power or cost advantage.
Capital has been diverted from the core business into loans for a subsidiary and current investments in mutual funds. While a preferential allotment raised significant cash, the funds have yet to generate an operational return, and the company remains loss-making on a consolidated basis.
The company's pivot to a new business segment failed to gain any traction, leaving the parent entity as a hollow shell with zero operational revenue. The cash raised through preferential allotment was slowly drained by administrative overhead and non-productive loans to subsidiaries rather than generating a return. As the investment income from mutual funds proved insufficient to cover persistent consolidated losses, the market eventually re-rated the stock to reflect its lack of a viable business model, resulting in a permanent loss of capital.
RichFakir rates Relic Technologies Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Relic Technologies Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →